Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

61  Enrolling
130  Total Trials
Pinned
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a...
Enrolling
Conditions: Atherosclerosis, Dyslipidemia
Trial Name
ACCLAIM-Lp(a)
Drugs: Lepodisiran
Age
≥18 years
Phase
III
Pinned
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Enrolling
Conditions: Rheumatoid Arthritis
Drugs: LY3871801
Age
≥18 years
Phase
II
Pinned
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Enrolling
Conditions: Diabetic Peripheral Neuropathy
Drugs: LY3556050
Age
≥18 years
Phase
II
Pinned
A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrolling
Conditions: Heart Failure
Drugs: LY3540378
Age
≥18 years
Phase
II
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LU...
Enrolling
Conditions: Ulcerative Colitis
Trial Name
LUCENT 3
Drugs: Mirikizumab
Age
18 - 80 years
Phase
III
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)
Enrolling
Conditions: Crohn's Disease
Trial Name
VIVID-2
Drugs: Mirikizumab
Age
≥18 years
Phase
III
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-...
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-4
Drugs: Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Age
≥18 years
Phase
III
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Enrolling
Conditions: Alzheimer Disease
Drugs: Mevidalen
Age
50 - 80 years
Phase
II
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Enrolling
Conditions: Alzheimer's disease
Drugs: donanemab
Age
60 - 85 years
Phase
III
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Enrolling
Conditions: Alzheimer's Disease
Drugs: LY3954068, Flortaucipir F18
Age
50 - 85 years
Phase
I
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-O...
Enrolling
Conditions: Crohn's Disease
Trial Name
SHINE-ON
Drugs: Mirikizumab
Age
2 - 19 years
Phase
III
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Enrolling
Conditions: Multiple sclerosis
Drugs: LY3541860
Age
18 - 55 years
Phase
II
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREA...
Enrolling
Conditions: Obesity, Overweight, Chronic Kidney Disease with or without Type 2 Diabetes
Trial Name
TREASURE-CKD
Drugs: Tirzepatide
Age
≥18 years
Phase
II
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: lebrikizumab, topical corticosteroid
Age
≥12 years
Phase
III
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Withou...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-5
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)
Enrolling
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1 year - 18 years
Phase
III
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS1
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
Enrolling
Conditions: Migraine
Trial Name
PIONEER-PEDS2
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)
Enrolling
Conditions: Obesity, Overweight and Cardiovascular Disease
Trial Name
TRIUMPH-3
Drugs: Retatrutide
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Enrolling
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With...
Enrolling
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-2
Drugs: retatrutide, semaglutide
Age
≥18 years
Phase
III
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)
Enrolling
Conditions: Solid tumors
Trial Name
NEXUS-01
Drugs: LY4052031
Age
≥18 years
Phase
I
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Enrolling
Conditions: Bladder Cancer, Advanced Solid Tumors
Drugs: LOX-24350 / LOXO-435, Pembrolizumab
Age
≥18 years
Phase
I
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
Enrolling
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2 - 17 years
Phase
III
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
Enrolling
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6 - 17 years
Phase
III
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Enrolling
Conditions: Obesity
Trial Name
SURMOUNT-ADOLESCENTS-2
Drugs: tirzepatide
Age
12 - 17 years
Phase
III
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
Enrolling
Conditions: Obesity, Overweight, Type 2 Diabetes, Sleep Apnea
Trial Name
TRIUMPH-2
Drugs: Retatrutide
Age
≥18 years
Phase
III
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)
Enrolling
Conditions: Obesity, Overweight, Osteoarthritis, Sleep Apnea
Trial Name
TRIUMPH-1
Drugs: Retatrutide
Age
≥18 years
Phase
III
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Enrolling
Conditions: Obese, Overweight
Drugs: Orforglipron (LY3502970)
Age
18 - 65 years
Phase
I
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Enrolling
Conditions: Lung Cancer, Colorectal Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, Uterine Cancer
Drugs: LY4170156
Age
≥18 years
Phase
I
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Enrolling
Conditions: Obesity
Drugs: retatrutide
Age
18 - 60 years
Phase
I
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine (REBUILD-1)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-1
Drugs: Galcanezumab
Age
6 - 17 years
Phase
III
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Enrolling
Conditions: Hidradenitis Suppurativa
Drugs: Eltrekibart
Age
18 - 75 years
Phase
II
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Enrolling
Conditions: Obesity
Drugs: Tirzepatide (LY3298176), Mibavademab
Age
≥18 years
Phase
II
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Typ...
Enrolling
Conditions: Obesity, Overweight, Chronic kidney disease
Drugs: retatrutide
Age
≥18 years
Phase
II
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine (REBUILD-2)
Enrolling
Conditions: Migraine
Trial Name
REBUILD-2
Drugs: Galcanezumab
Age
12 - 17 years
Phase
III
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Enrolling
Conditions: Obesity, Overweight
Drugs: LY3841136
Age
18 - 75 years
Phase
II
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Enrolling
Conditions: Obesity
Drugs: Mazdutide
Age
18 - 75 years
Phase
II
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (SHINE-2)
Enrolling
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2 - 17 years
Phase
III
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in ...
Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
SUNRAY-01
Drugs: LY3537982, Pemetrexed, Pembrolizumab, Cisplatin, Carboplatin
Age
≥18 years
Phase
III
A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)
Enrolling
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRANCH
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Enrolling
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1 year - 17 years
Phase
III
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Enrolling
Conditions: Type 2 Diabetes, Obesity
Drugs: Tirzepatide (LY3298176)
Age
18 - 75 years
Phase
II
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise ...
Enrolling
Conditions: Type 2 Diabetes
Trial Name
TRANSCEND-T2D-1
Drugs: retatrutide
Age
≥18 years
Phase
III
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glyc...
Enrolling
Conditions: Type 2 diabetes
Trial Name
TRANSCEND-T2D-3
Drugs: retatrutide
Age
≥18 years
Phase
III
A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)
Enrolling
Conditions: COVID-19
Trial Name
COV-BARRIER-PEDS
Drugs: Baricitinib, LY3009104
Age
2 - 18 years
Phase
III
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Enrolling
Conditions: Lung Cancer, Advanced Solid Tumors
Drugs: LY3537982, pembrolizumab, cetuximab, pemetrexed, cisplatin
Age
≥18 years
Phase
I
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Enrolling
Conditions: Solid tumors
Drugs: LY4101174
Age
≥18 years
Phase
I
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Enrolling
Conditions: Atopic Dermatitis (Eczema)
Drugs: Ucenprubart
Age
18 - 70 years
Phase
II
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Enrolling
Conditions: Hepatic Impairment, Healthy Participants
Drugs: Orforglipron
Age
18 - 80 years
Phase
I
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease
Enrolling
Conditions: Non-Alcoholic Fatty Liver Disease
Drugs: LY3849891
Age
18 - 70 years
Phase
I
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lym...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-322
Drugs: Pirtobrutinib, Rituximab, Venetoclax
Age
≥18 years
Phase
III
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Enrolling
Conditions: Plaque Psoriasis
Drugs: LY3972406
Age
18 - 75 years
Phase
II
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma (CAMPFIRE)
Enrolling
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1 year - 39 years
Phase
II
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Enrolling
Conditions: Type 1 diabetes, Healthy volunteers
Drugs: LY3938577, insulin degludec, insulin lispro
Age
18 - 64 years
Phase
I
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Enrolling
Conditions: Obesity
Drugs: LY3841136
Age
18 - 65 years
Phase
I
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Enrolling
Conditions: Perennial Allergic Rhinitis (PAR)
Trial Name
PREPARED-1
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids...
Enrolling
Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Drugs: Lebrikizumab (LY3650150)
Age
≥18 years
Phase
III
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)
Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
LIBRETTO-432
Drugs: Selpercatinib
Age
≥18 years
Phase
III

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
4  Not Yet Enrolling
130  Total Trials
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Not Yet Enrolling
Conditions: Pain
Drugs: LY3848575
Age
≥18 years
Phase
II
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Not Yet Enrolling
Conditions: Type 2 diabetes
Drugs: LY3209590
Age
10 - 17 years
Phase
I
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radi...
Not Yet Enrolling
Conditions: High-Grade Glioma
Drugs: abemaciclib, temozolomide
Age
≤20 years
Phase
II
A Study of LY3532226 in Participants With Obesity
Not Yet Enrolling
Conditions: Obesity
Drugs: LY3532226
Age
18 - 65 years
Phase
I
65 
Completed Enrollment
130  Total Trials
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Completed Enrollment
Conditions: Ulcerative Colitis
Trial Name
LUCENT 2
Drugs: Mirikizumab, Placebo
Age
18 - 80 years
Phase
III
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)
Completed Enrollment
Conditions: Rheumatoid Arthritis
Trial Name
RA-BRIDGE
Drugs: Baricitinib, TNF Inhibitor
Age
≥18 years
Phase
IV
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)
Completed Enrollment
Conditions: Breast Cancer, Advanced Solid Tumors
Trial Name
PIKASSO-01
Drugs: LOXO-783
Age
≥18 years
Phase
I
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
Completed Enrollment
Conditions: Obesity
Trial Name
SURMOUNT-MMO
Drugs: Tirzepatide
Age
≥40 years
Phase
III
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to ...
Completed Enrollment
Conditions: Prostate Cancer
Trial Name
CYCLONE 3
Drugs: Abemaciclib, Abiraterone, LY2835219, Prednisone, Prednisolone
Age
≥18 years
Phase
III
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic N...
Completed Enrollment
Conditions: Non-Small Cell Lung Cancer
Trial Name
RELAY
Drugs: Ramucirumab, Erlotinib
Age
≥18 years
Phase
III
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
SURPASS-EARLY
Drugs: Antihyperglycemic medication, Tirzepatide
Age
≥18 years
Phase
IV
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
TRAILBLAZER-ALZ 3
Drugs: Donanemab, LY3002813
Age
65 - 80 years
Phase
III
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
postMONARCH
Drugs: Abemaciclib, Fulvestrant
Age
≥18 years
Phase
III
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Adv...
Completed Enrollment
Conditions: Breast Cancer
Trial Name
EMBER-3
Drugs: LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib
Age
≥18 years
Phase
III
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Completed Enrollment
Conditions: Breast Cancer, Endometrial Cancer
Trial Name
EMBER
Drugs: LY3484356, Abemaciclib
Age
≥18 years
Phase
I
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Completed Enrollment
Conditions: Neuroblastoma
Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Age
2 - 21 years
Phase
I
A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
Completed Enrollment
Conditions: Alzheimer's Disease
Drugs: LY3372993
Age
18 - 85 years
Phase
I
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Completed Enrollment
Conditions: Breast Cancer
Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane
Age
≥18 years
Phase
I
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)
Completed Enrollment
Conditions: Obesity
Trial Name
ATTAIN-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACH...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-3
Drugs: Orforglipron, Semaglutide
Age
≥18 years
Phase
III
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)
Completed Enrollment
Conditions: Ulcerative Colitis
Trial Name
LUCENT-URGE
Drugs: Mirikizumab
Age
≥18 years
Phase
III
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-J
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)
Completed Enrollment
Conditions: Overweight, Obesity
Trial Name
SURMOUNT-5
Drugs: Tirzepatide, Semaglutide
Age
≥18 years
Phase
III
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (A...
Completed Enrollment
Conditions: Type 2 Diabetes
Trial Name
ACHIEVE-1
Drugs: Orforglipron
Age
≥18 years
Phase
III
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight a...
Completed Enrollment
Conditions: Type 2 Diabetes, Overweight at Increased Cardiovascular Risk
Trial Name
ACHIEVE-4
Drugs: Orforglipron (LY3502970), Insulin Glargine
Age
≥18 years
Phase
III
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Completed Enrollment
Conditions: Alzheimer's disease
Trial Name
TRAILRUNNER-ALZ 1
Drugs: Remternetug (LY3372993)
Age
60 - 85 years
Phase
III
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anteri...
Completed Enrollment
Conditions: Uveitis
Drugs: Baricitinib, Adalimumab
Age
2 - 17 years
Phase
III
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease (PROSPECT-ALZ)
Completed Enrollment
Conditions: Alzheimer's Disease
Trial Name
PROSPECT-ALZ
Drugs: LY3372689
Age
60 - 85 years
Phase
II
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
Completed Enrollment
Conditions: Aicardi Goutieres Syndrome (AGS)
Drugs: Baricitinib
Age
≥6 months
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, B-cell Leukemias, Small Lymphocytic Lymphomas
Trial Name
BRUIN-CLL-314
Drugs: Pirtobrutinib, Ibrutinib
Age
≥18 years
Phase
III
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (I9Y-OX-JDHB)
Completed Enrollment
Conditions: Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
Trial Name
I9Y-OX-JDHB
Drugs: LY3410738
Age
≥18 years
Phase
I
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3410738
Age
≥18 years
Phase
I
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Completed Enrollment
Conditions: Blood Cancers
Drugs: LOXO-338 / LY3847429, Pirtobruitinib
Age
≥18 years
Phase
I
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (CAMPFIRE)
Completed Enrollment
Conditions: Desmoplastic Small Round Cell Tumor
Trial Name
CAMPFIRE
Drugs: Cyclophosphamide, Ramucirumab, Vinorelbine
Age
12 months - 29 years
Phase
II
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)
Completed Enrollment
Conditions: Alopecia Areata (Hair Loss)
Trial Name
BRAVE-AA2
Drugs: Baricitinib, Placebo
Age
18 - 70 years
Phase
III
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (JUVE-BASIS)
Completed Enrollment
Conditions: Lung Cancer, Thyroid Cancer and other Solid Tumors
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12 years
Phase
I
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-321
Drugs: Bendamustine, Idelalisib, LOXO-305, Rituximab
Age
≥18 years
Phase
III
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Completed Enrollment
Conditions: Alzheimer's disease
Drugs: donanemab